Jheelam Banerjee

Jheelam Banerjee

Auto-generated profile, based on publicly available information

Jheelam Banerjee

NuSirt Biopharma Inc., 11020 Solway School Rd, Knoxville, TN 37931, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2016 in International Journal of Hepatology
Verified
Journal Article
Open access
PDF file
ABAntje Bruckbauer
Antje Bruckbauer
JBJheelam Banerjee
Jheelam Banerjee
LFLizhi Fu
Lizhi Fu
FLFenfen Li
Fenfen Li
QCQiang Cao
Qiang Cao
MZMichael Zemel
Michael Zemel
Sirt1, AMPK, and eNOS modulate hepatic energy metabolism and inflammation and are key players in the development of NASH. L-leucine, an allosteric Sirt1 activator, synergizes with low doses of metformin or sildenafil on the AMPK-eNOS-Sirt1 pathway to reverse mild NAFLD in preclinical mouse models. Here we tested a possible multicomponent synergy to yield greater therapeutic efficacy in NAFLD/NASH. Liver cells and macrophages or an atherogenic diet induced NASH mouse model was treated with two-way and three-way combinations. The three-way combination Sild-Met-Leu increased hepatic fatty acid oxidation and reduced lipogenic gene expression and inflammatory marker in vitro. In mice, Sild-Met-Leu reduced the diet induced increases of ALT, TGFβ, PAI-1, IL1β, and TNFα, hepatic collagen expression, and nearly completely reversed hepatocyte ballooning and triglyceride accumulation, while all two-way combinations had only modest effects. Therefore, these data provide preclinical evidence for therapeutic efficacy of Sild-Met-Leu in the treatment of NAFLD and NASH.